Lyra Therapeutics (LYRA) Other Accumulated Expenses (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Other Accumulated Expenses for 7 consecutive years, with $518000.0 the latest figure, recorded in Q4 2025.

• Other Accumulated Expenses for Q4 2025 came in at $518000.0, up 9.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $518000.0 (up 9.05% YoY), and the FY2025 annual result was $518000.0, up 9.05% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $518000.0, up from $475000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.2 million in Q4 2023, with the low at $40000.0 in Q1 2022.
• A 5-year average of $384454.5 and a median of $299000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 324.83% in 2021 and sank 61.41% in 2024, its largest moves.
• Lyra Therapeutics' Other Accumulated Expenses stood at $633000.0 in 2021, then rose by 4.11% to $659000.0 in 2022, then jumped by 86.8% to $1.2 million in 2023, then slumped by 61.41% to $475000.0 in 2024, then advanced by 9.05% to $518000.0 in 2025.
• The last three Other Accumulated Expenses figures came in at $518000.0 (Q4 2025), $475000.0 (Q4 2024), and $1.2 million (Q4 2023), per Business Quant data.